Conclusion & Future Perspective
mRCC is a heterogeneous disease. Therefore, the identification of prognostic factors able to guide therapeutic decisions is of major importance. In recent years, these factors have been incorporated into complex models, such as the Motzer criteria, which have been validated by robust studies. However, these models should be integrated with more parameters to better predict clinical outcomes.
We believe that the metastatic site can be incorporated into such models, in order to help clinicians evaluate risk and outcomes of each single patient. In the next years, prospective studies will likely be planned to address this issue, and provide clinicians with more refined prognostic models able to tailor treatment decisions on the characteristics of each single patient.